ライフサイエンスコーパス: cis-diamminedichloroplatinum

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 of cells to the anticancer agent cisplatin (cis-diamminedichloroplatinum, CDDP) is associated with c

2 ependent apoptosis of U87-MG glioma cells by cis-diamminedichloroplatinum (cisplatin), and overexpres

3 -bis(2-chloroethyl)-1-nitrosourea (BCNU) and cis-diamminedichloroplatinum (cisplatin), in an isogenei

4 human breast carcinoma BT549 cells inhibits cis-diamminedichloroplatinum (cisplatin)-induced poly(AD

5 In this study, we used cis-diamminedichloroplatinum (cisplatin)-sensitive U87-M

6 ed by the widely used chemotherapeutic agent cis-diamminedichloroplatinum (cisplatin).

7 A cis-diamminedichloroplatinum [DDP (cisplatin)]-resistant

8 Either a conventional cis-diamminedichloroplatinum (II) (CDDP) or a bulky CDDP

9 athways play an important role in modulating cis-Diamminedichloroplatinum (II) (cisplatin) cytotoxici

10 hat the DNA-damaging chemotherapeutic drugs, cis-diamminedichloroplatinum(II) (CDDP) and etoposide, e

11 cell death mediated by the anticancer agent cis-diamminedichloroplatinum(II) (cDDP) is influenced by

12 ught to identify novel genes associated with cis-diamminedichloroplatinum(II) (CDDP) resistance, and

13 The chemotherapeutic drug cisplatin (cis-diamminedichloroplatinum(II) (CDDP)) is widely used

14 cis-Diamminedichloroplatinum(II) (CDDP), which is mostly

15 nd enhanced the growth inhibitory actions of cis-diamminedichloroplatinum(II) (CDDP).

16 cis-Diamminedichloroplatinum(II) (cis-DDP or cisplatin)

17 Mapping of cis-diamminedichloroplatinum(II) (cis-DDP, cisplatin) DN

18 The anticancer activity of cis-diamminedichloroplatinum(II) (cisplatin) arises from

19 The antitumor agent cis-diamminedichloroplatinum(II) (cisplatin) introduces

20 cis-Diamminedichloroplatinum(II) (cisplatin) is a widely

21 cis-Diamminedichloroplatinum(II) (cisplatin) is able to

22 As a widely used anticancer drug, cis-diamminedichloroplatinum(II) (cisplatin) reacts with

23 Cis-diamminedichloroplatinum(II) (cisplatin)-induced ren

24 one (GSH) levels were remarkably enhanced in cis-diamminedichloroplatinum(II) (cisplatin)-resistant h

25 emotherapy with the platinum-containing drug cis-diamminedichloroplatinum(II) (cisplatin).

26 to the damage produced by the clinical agent cis-diamminedichloroplatinum(II) (cisplatin, 1).

27 of CTR2 increased the tumor accumulation of cis-diamminedichloroplatinum(II) [cisplatin (cDDP)] by 9

28 suggest that recognition of 1,2-intrastrand cis-diamminedichloroplatinum(II) adducts by MutSalpha ma

29 ross-linking studies with the antitumor drug cis-diamminedichloroplatinum(II) and its clinically inac

30 seen in the protection of cells treated with cis-diamminedichloroplatinum(II) but not with anti-(+/-)

31 site-specific enhancement and depression of cis-diamminedichloroplatinum(II) cross-linking in the nu

32 A modified by the anticancer drug cisplatin (cis-diamminedichloroplatinum(II) or cis-DDP); among thes

33 The cancer chemotherapeutic agent cis-diamminedichloroplatinum(II) or cisplatin reacts pri

34 library for proteins that bind to cisplatin (cis-diamminedichloroplatinum(II))-modified DNA, contains

35 1,2-intrastrand d(GpG) crosslink produced by cis-diamminedichloroplatinum(II), as well as base pairs

36 damage-inducing agents, including cisplatin (cis-diamminedichloroplatinum(II), CDDP), a cancer chemot

37 efore and after treatment with camptothecin, cis-diamminedichloroplatinum(II), hydroxyurea, or 5-fluo

38 n of platinum-based anticancer drugs such as cis-diamminedichloroplatinum(II), or cisplatin, involves

39 nal binding of the antitumor drug cisplatin, cis-diamminedichloroplatinum(II), to a purine base site

40 endent protein kinase (DNA-PK) inhibition by cis-diamminedichloroplatinum(II)-(cisplatin-) damaged DN

41 ne doxorubicin-resistant and two independent cis-diamminedichloroplatinum(II)-resistant derivatives a

42 oxy-d-glucose (2DG) combined with cisplatin [cis-diamminedichloroplatinum(II)] can enhance cytotoxici

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。